Consensus Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Real-time Euronext Paris Other stock markets 06:39:02 2024-04-25 am EDT			5-day change	1st Jan Change
205.9 ^EUR	-1.15%		-1.77%	-14.03%

Apr. 23	SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	ZD
Apr. 22	Sartorius Stedim: in the red with brokerage comments	CF

Evolution of the average Target Price on Sartorius Stedim Biotech

Price target over the last 5 years

History of analyst recommendation changes

ce8f9e2340f7e.TExFg4dR0CCfUfkAMLpd7EOjT_AhGhjGfb9BUv5uWks.BwQD8dBhlRfRE4hKePEW3TCXAKNCIkuOHNkoMc8JAAMcNRLExBulTMoHmg~f699f4a9f2bac3c4b67a8cabfcb22dd3

Analyst Recommendations on Sartorius Stedim Biotech

SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	Apr. 23	ZD
Sartorius Stedim: in the red with brokerage comments	Apr. 22	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	Apr. 22	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	Apr. 22
SARTORIUS STEDIM : UBS reduces target price	Apr. 22	CF
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	Mar. 12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	Feb. 16	MT
SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’	Jan. 30
SARTORIUS STEDIM : UBS raises its target price	Jan. 29	CF
Sartorius thwarted by 21-day line - despite HSBC recommendation	Jan. 10	DP
JPMORGAN : Sartorius outlook likely to be share price driver	Jan. 02	DP
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	Dec. 19
Sartorius continues to slide - low since April 2020	23-10-23	DP
Sartorius and subsidiary recover - JPMorgan praises biotech orders	23-10-19	DP
SARTORIUS STEDIM BIOTECH : Disappointing preliminary Q3 23 puts mid-term outlook in question	23-10-17
Profit warning weighs heavily on Sartorius and subsidiary Stedim	23-10-13	DP
SARTORIUS STEDIM BIOTECH : Jefferies reiterates its Buy rating	23-09-29	ZD
Chinese headwinds could be more severe than expected	23-09-22
German Stocks Extend Losses Amid Rate Jitters Ahead of Monetary Policy Week	23-09-08	MT
SARTORIUS STEDIM BIOTECH : Jefferies gives a Buy rating	23-09-06	ZD
SARTORIUS STEDIM BIOTECH : Credit Suisse remains Neutral	23-08-11	ZD
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	23-07-25
SARTORIUS STEDIM BIOTECH : Q2 23 weakness overshadowed by positive management commentary	23-07-21
SARTORIUS STEDIM BIOTECH : UBS reiterates its Buy rating	23-06-20	ZD
SARTORIUS STEDIM BIOTECH : Gets a Buy rating from JP Morgan	23-06-19	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

208.3 EUR

Average target price

251.3 EUR

Spread / Average Target

+20.66%

High Price Target

360 EUR

Spread / Highest target

+72.83%

Low Price Target

200 EUR

Spread / Lowest Target

-3.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sartorius Stedim Biotech

UBS
alphavalue	Virendra Chauhan
BARCLAYS	Charles Pitman
JEFFERIES	James Vane-Tempest
CREDIT SUISSE	Dominic Lunn
JPMORGAN	Richard Vosser
HSBC	Rajesh Kumar
BERENBERG	Odysseas Manesiotis

Ratings for Sartorius Stedim Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar